SCHEMBL2204435

SCHEMBL2204435

COc1ccc(N)c(C=O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.61
ALDH1A1 P00352 10/20 0.58
TRIM24 O15164 1/20 0.56
TYR P14679 1/20 0.56
TRIM33 Q9UPN9 1/20 0.56
CYP3A4 P08684 1/20 0.52
CYP1A2 P05177 4/20 0.49
MAPT P10636 3/20 0.49
KDM4E B2RXH2 2/20 0.49
CYP2C19 P33261 2/20 0.49
MEN1 O00255 2/20 0.47
THRB P10828 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP2A6 P11509 1/20 0.47
GAA P10253 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
MCL1 Q07820 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL28373237 0.91 ERN1 (0.57) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL29957021 0.85 ALDH1A1 (0.70) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL12672585 0.85 ALDH1A1 (0.70) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL1571550 0.84 ALDH1A1 (0.63) ERN1ALDH1A1TRIM24TYRTRIM33
Ethylene SCHEMBL8310436 0.82 ERN1 (0.44) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL20961911 0.80 ALDH1A1 (0.52) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL28336721 0.80 ALDH1A1 (0.52) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL3214487 0.79 MEN1 (0.54) ERN1ALDH1A1CYP3A4MAPTKDM4E
SCHEMBL3209341 0.79 ALDH1A1 (0.41) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL10861186 0.78 ALDH1A1 (0.61) ERN1ALDH1A1TRIM24TYRTRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111039993-B Ruthenium acetylacetonate complex and application thereof in hydrogen production by photolysis of water 云南大学 2020-11-13 CN claimed
CN-111039993-A Ruthenium acetylacetonate complex and application thereof in hydrogen production by photolysis of water 云南大学 2020-04-21 CN claimed
CN-107522766-B Ursolic acid quinolyl hydrazide derivatives with anti-tumor activity and preparation method and application thereof 南京林业大学 2020-03-27 CN claimed
EP-4622967-A1 COMPOUNDS THAT INHIBIT PKMYT1 Exelixis, Inc. (US) 2025-10-01 EP disclosed
WO-2024222866-A1 CYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO., LTD. (CN) 2024-10-31 WO disclosed
WO-2024112853-A1 COMPOUNDS THAT INHIBIT PKMYT1 EXELIXIS, INC. (US) 2024-05-30 WO disclosed
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER CISTIM LEUVEN VZW (BE) 2024-01-25 US disclosed
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER CISTIM LEUVEN VZW (BE) 2024-01-25 US disclosed
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER CISTIM LEUVEN VZW (BE) 2024-01-25 US disclosed
CN-116783165-A 1,2,3, 4-tetrahydroquinoline derivatives as YAP/TAZ-TEAD activation inhibitors for the treatment of cancer 天主教鲁汶大学 2023-09-19 CN disclosed
EP-4222143-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER Katholieke Universiteit Leuven (BE) 2023-08-09 EP disclosed
EP-0436653-A1 SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF RESEARCH TRIANGLE INSTITUTE (US) 1991-07-17 EP disclosed
WO-1991005556-A1 CAMPTOTHECIN ANALOGS AS POTENT INHIBITORS OF HUMAN COLORECTAL CANCER RESEARCH TRIANGLE INSTITUTE (US) 1991-05-02 WO disclosed
US-4981968-A ENZYME INHIBITORS, ANTITUMOR RESEARCH TRIANGLE INSTITUTE (US) 1991-01-01 US disclosed
WO-1990003169-A1 SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF RESEARCH TRIANGLE INSTITUTE (US) 1990-04-05 WO disclosed
US-4894456-A CYCLIZATION, ESTERIFICATION RESEARCH TRIANGLE INSTITUTE (US) 1990-01-16 US disclosed
US-4806657-A REACTING KETON ACID WITH 4-FORMYLAMINOPHENOL; DECARBONYLATION, CYCLIZATION AND CONDENSATION CIBA-GEIGY CORPORATION (US) 1989-02-21 US disclosed
EP-0093922-B1 BENZOXAZIN-2-ONES, THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THESE COMPOUNDS Dr. Karl Thomae GmbH (DE) 1986-12-30 EP disclosed
US-4518597-A THROMBOSIS, ARTERIOSCLEROSIS, ANTITUMOR, ANTICOAGULANTS DR. KARL THOMAE GMBH (DE) 1985-05-21 US disclosed
EP-0093922-A2 Benzoxazin-2-ones, their preparation and therapeutic agents containing these compounds Dr. Karl Thomae GmbH (DE) 1983-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER YAP1, TEAD2, TEAD1 ERN1 2606/4885ALDH1A1 1569/4885TRIM24 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.